KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 93 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,838,913 | +10.0% | 1,644,747 | +2.8% | 0.00% | – |
| Q2 2023 | $14,397,642 | +17.6% | 1,599,738 | +2.7% | 0.00% | – |
| Q1 2023 | $12,246,934 | +15.2% | 1,558,134 | -0.9% | 0.00% | – |
| Q4 2022 | $10,629,566 | -57.1% | 1,572,421 | -7.8% | 0.00% | -100.0% |
| Q3 2022 | $24,757,000 | +50.5% | 1,706,148 | +2.1% | 0.00% | 0.0% |
| Q2 2022 | $16,448,000 | -27.7% | 1,671,495 | +8.3% | 0.00% | 0.0% |
| Q1 2022 | $22,757,000 | +14.3% | 1,544,027 | +2.6% | 0.00% | 0.0% |
| Q4 2021 | $19,906,000 | -19.5% | 1,504,620 | +6.2% | 0.00% | 0.0% |
| Q3 2021 | $24,720,000 | -27.7% | 1,416,642 | -0.7% | 0.00% | 0.0% |
| Q2 2021 | $34,178,000 | -14.7% | 1,426,422 | -8.5% | 0.00% | 0.0% |
| Q1 2021 | $40,062,000 | +89.5% | 1,559,488 | +40.1% | 0.00% | 0.0% |
| Q4 2020 | $21,143,000 | +83.6% | 1,113,380 | +21.7% | 0.00% | – |
| Q3 2020 | $11,517,000 | +3.0% | 914,734 | -1.0% | 0.00% | – |
| Q2 2020 | $11,179,000 | +67.5% | 923,851 | +5.9% | 0.00% | – |
| Q1 2020 | $6,674,000 | -56.5% | 872,457 | +1.4% | 0.00% | -100.0% |
| Q4 2019 | $15,327,000 | +72.4% | 860,633 | +12.3% | 0.00% | – |
| Q3 2019 | $8,890,000 | -45.5% | 766,512 | +4.0% | 0.00% | -100.0% |
| Q2 2019 | $16,320,000 | +711.5% | 736,782 | +948.7% | 0.00% | – |
| Q1 2019 | $2,011,000 | +125.7% | 70,257 | +55.9% | 0.00% | – |
| Q4 2018 | $891,000 | +108.7% | 45,078 | +133.5% | 0.00% | – |
| Q3 2018 | $427,000 | +223.5% | 19,309 | +19.2% | 0.00% | – |
| Q2 2018 | $132,000 | +164.0% | 16,205 | +203.8% | 0.00% | – |
| Q1 2018 | $50,000 | +2.0% | 5,334 | +7.4% | 0.00% | – |
| Q4 2017 | $49,000 | +53.1% | 4,966 | +5.0% | 0.00% | – |
| Q3 2017 | $32,000 | 0.0% | 4,730 | +9.2% | 0.00% | – |
| Q2 2017 | $32,000 | +18.5% | 4,331 | +26.7% | 0.00% | – |
| Q1 2017 | $27,000 | – | 3,418 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |